<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03336385</url>
  </required_header>
  <id_info>
    <org_study_id>FIT</org_study_id>
    <nct_id>NCT03336385</nct_id>
  </id_info>
  <brief_title>Prebiotic Supplementation and Intestinal Barrier Function in Elderly: a RCT</brief_title>
  <official_title>The Influence of Prebiotic Supplementation on Intestinal Barrier Function in Elderly: A Randomized Placebo Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Örebro University, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fibebiotics consortium (EU)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Örebro University, Sweden</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim was to assess whether 6 weeks of oral intake of the wheat-derived
      prebiotic fiber arabinoxylan or oat-derived beta-glucan could improve intestinal barrier
      function against drug-induced barrier disruption in a general population of elderly people,
      in a randomized double blinded placebo-controlled clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consisted of a 9 week clinical trial to which the study participants orally
      ingested two different prebiotic compounds/one placebo for a total of 6 weeks.

      The primary outcome was intestinal permeability which was measured before/after indomethacin
      intake before starting with the prebiotic supplementation and repeated 6 weeks afterwards.

      Indomethacin is an NSAID known to artificially increase the intestinal permeability. The
      prebiotic fibers arabinoxylan and oat-derived beta-glucan have not been investigated for
      their effect on intestinal permeability in older adults.

      Intestinal permeability was investigated using the multi-sugar permeability test.
      Participants ingested a water solution containing 5 sugar probes that are taken up in
      different parts of the gut. These sugars are later recovered in the urine at two different
      time points, reflecting gastroduodenal, small intestinal and colonic permeability.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2015</start_date>
  <completion_date type="Actual">December 18, 2015</completion_date>
  <primary_completion_date type="Actual">December 18, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study participants were allocated through block randomization into three different intervention arms that ran in parallell throughout the study</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The randomization list was generated and provided by the Fibebiotics consortium (part of the EU framework 7 program) using unique study codes for participants.
All study product labels were coded by a third-party. All investigators and study participants remained blinded until final analysis</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in delta indomethacin challenged permeability at end of intervention period</measure>
    <time_frame>6 weeks</time_frame>
    <description>In vivo multi-sugar permeability test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in faecal microbiota composition at end of intervention period</measure>
    <time_frame>6 weeks</time_frame>
    <description>16S rRNA-based sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cytokine levels at end of intervention period</measure>
    <time_frame>6 weeks</time_frame>
    <description>Multiplex assay for IL-1β, IL-6, IL-8, IL-10, IL-2, IL-12p70, IFN-γ and TNF-α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in reactive oxygen species levels at end of intervention period</measure>
    <time_frame>6 weeks</time_frame>
    <description>FORT test for hydrogen peroxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gastrointestinal symptom questionnaire scores at end of intervention period</measure>
    <time_frame>6 weeks</time_frame>
    <description>GSRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hospital and anxiety depression scores at end of intervention period</measure>
    <time_frame>6 weeks</time_frame>
    <description>HADS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in perceived stress scale scores at end of intervention period</measure>
    <time_frame>6 weeks</time_frame>
    <description>PSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life questionnaire scores at end of intervention period</measure>
    <time_frame>6 weeks</time_frame>
    <description>EG-5D-5L</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Prebiotics</condition>
  <condition>Aged</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin 12 gram used as placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naxus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naxus contains the wheat-derived prebiotic fibre Arabinoxylan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oatwell</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oatwell contains an oat-derived prebiotic beta-glucan fibre</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Naxus</intervention_name>
    <description>Non-digestible polysaccharides arabinoxylan (Naxus)</description>
    <arm_group_label>Naxus</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oatwell</intervention_name>
    <description>Non-digestible polysaccharides oat beta-glucan (Oatwell)</description>
    <arm_group_label>Oatwell</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin as placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent signed by study participant

          -  Age ≥ 55 years

          -  Mentally and physically fit to complete questionnaires during the study period

        Exclusion Criteria:

          -  Known or genic gastrointestinal disease, with strictures, malignance's and ischemia.

          -  Inflammatory bowel diseases (IBD)

          -  Participation in other clinical trials in the past three months.

          -  Intake of medications know to change the inflammatory status (i.e proton pump
             inhibitors, antibiotic, anti-inflammatory medication (including NSAIDs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Brummer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Örebro University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Örebro University</name>
      <address>
        <city>Örebro</city>
        <zip>701 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Örebro University, Sweden</investigator_affiliation>
    <investigator_full_name>Robert Brummer</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>Older adults</keyword>
  <keyword>Prebiotics</keyword>
  <keyword>Intestinal permeability</keyword>
  <keyword>NSAIDS</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

